U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
about
CIViC databaseClinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutationsAberrant splicing and drug resistance in AMLDown-regulation of GPX3 is associated with favorable/intermediate karyotypes in de novo acute myeloid leukemiaGPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemiaDecitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b StudyReduced miR-215 expression predicts poor prognosis in patients with acute myeloid leukemiaPseudogene BMI1P1 expression as a novel predictor for acute myeloid leukemia development and prognosis.GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndromeEpigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia.Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia.BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia.Splicing factor gene mutations in hematologic malignancies.Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia.The prognostic implication of SRSF2 mutations in Chinese patients with acute myeloid leukemia.Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia.Reduced expression of chemerin is associated with poor clinical outcome in acute myeloid leukemia.High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia.Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia.Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia.H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia.Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies.GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemiaOverexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia
P2860
Q27612411-EBF2DF86-79B5-4504-878D-440FB5FBE472Q27852437-B3EF2ECF-FF7B-4E1C-AA03-AD0CD6A40545Q27853094-EC70E939-F7C2-4178-A178-BDA2F3E4AB39Q28076011-74D6D364-6FCB-44D3-8BD5-BE0D27B0C521Q35632014-8248BB83-9E3B-419A-8378-15A5DD790EF7Q35835260-7DDBE290-748D-41FF-824D-4D2F11F60A68Q35854158-BF6F1052-DA9C-4858-A321-5DEC950F8439Q36327153-B7355083-CFAF-49FF-8AC8-9D3AC2A486B5Q36949308-D90786E4-6B7B-409D-9DD9-626D573316F2Q37565147-F1DAA441-22CB-4236-BFF3-788EC14ACD3FQ37609224-CC81480C-BDF8-41D1-AFDC-C464A1915093Q37675993-6A6B9D39-ACC7-4F68-B93F-2B0BFF363174Q38074757-218620FF-7982-4A1F-ACF6-A3B0909ABBABQ38804780-D23D004D-5094-4D44-86AD-A077BFB75A4AQ38819676-C7D6EB27-CD89-4C24-90A3-B82F222980C2Q38839165-FB07934E-D3E5-4CA5-8C64-6C67DF4E7584Q39035441-16056C96-48D8-4AFC-BF0D-4A1DF5E4F068Q40371904-27384C0B-E09F-4EC4-B84C-CF6622C08C5BQ40601089-4791D6E9-9FDF-4841-8385-99B0C2EDDB14Q40945732-801B87FE-0450-45E4-9BF9-86B343FBB3C4Q41241298-00276455-56DC-4421-B67F-365EC0019FEAQ42371609-0A7D072D-76A7-435C-9499-F411FFA1EF74Q46670726-D79B63E6-865F-4098-B5FF-5284DF1283E7Q47346339-D025E423-4165-438D-BD10-2E5147E89D56Q48105461-AAF3E156-4AEA-4134-99AE-35A347090746Q48446071-D8D7103F-B7A4-4FF8-BED3-0F6E73E27D04Q55279230-FAE7FA89-D815-4393-B0B4-6CC923ACAA55Q55312785-6FC6EC7A-DCEE-4758-9AEA-E7C464D5A9A9Q55651366-A9F95A61-2F58-4585-992A-44C0B6894010Q56507614-69CAEDDF-267C-46B9-B571-BBF6E04FABBBQ59135325-D5A62D94-7788-4437-A358-6E99782ECA7D
P2860
U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@ast
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@en
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@nl
type
label
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@ast
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@en
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@nl
altLabel
U2AF1 Mutations in Chinese Pat ...... a and Myelodysplastic Syndrome
@en
prefLabel
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@ast
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@en
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@nl
P2093
P2860
P3181
P1433
P1476
U2AF1 mutations in Chinese pat ...... and myelodysplastic syndrome.
@en
P2093
Cui-zhu Wang
Dong-ming Yao
Hai-yan Chai
Ji-chun Ma
Xing-xing Chen
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0045760
P407
P577
2012-01-01T00:00:00Z